contraindications to glp 1 agonists for Using information from the NPF Medical Board's publication in JAMA Dermatology, Glucagon-Like Peptide-1 Receptor Agonists And

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration

no major safety concerns were observed

The Ozempic vision loss lawsuit involves claims that semaglutide medications, including Ozempic, Wegovy, and Rybelsus, may be associated with non-arteritic...

(WROC) Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs used to treat certain medical conditions remain cove...

Discover everything you need to know about GLP-1, from its biological functions and health benefits to weight loss, natural boosters, and medications.